Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kan He

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 1, 2021
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung CancerYayi He, Lele Song, Hao Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2009
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of AmericaScott W Grimm, Heidi J Einolf, Steven D Hall, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesDonald J P Pinto, Robert A Galemmo, Mimi L Quan, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Toxicology Reports|March 7, 2020
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extractsHellen A Oketch-Rabah, Amy L Roe, Cynthia V Rider, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 1, 2021
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung CancerYayi He, Lele Song, Hao Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2009
The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of AmericaScott W Grimm, Heidi J Einolf, Steven D Hall, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesDonald J P Pinto, Robert A Galemmo, Mimi L Quan, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Toxicology Reports|March 7, 2020
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extractsHellen A Oketch-Rabah, Amy L Roe, Cynthia V Rider, et al.
Pageof 19